29 April 2026
: Case report 
Hemolytic Glaucoma Following Intravitreal Aflibercept Injection for Age-Related Macular Degeneration: A Case Report
Diagnostic / therapeutic accidents
Hiroki Sano
ABDEF 1*, Ryoji Yanai DE 2, Yoshinori Mitamura DE 2
DOI: 10.12659/AJCR.952247
Am J Case Rep 2026; 27:e952247
Table 1 Summary of the clinical course, visual acuity, intraocular pressure, and management.
| Day | Clinical findings | BCVA | IOP (mmHg) | Management |
|---|---|---|---|---|
| 0 | 10 intravitreal aflibercept injection (uneventful) | 20/20 | 20 | – |
| 3 | Blurred vision (patient-reported; no clinical visit) | – | – | – |
| 4 | Hyphema with fluid level; fundus not visible | Hand motion | 20 | Started oral carbazochrome sodium sulfonate hydrate (30 mg TID) |
| 7 | Marked IOP elevation to 50 mmHg | Hand motion | 50 | Surgical intervention (AC irrigation + PPV + phacoemulsification) |
| Post-op day 1 | Clear AC; hyphema resolved | – | 10 | Post-op care |
| 2 weeks | Stable | 20/20 | 20 | Observation |
| 1 year | No recurrence; normal GCIPL | 20/16 | 18 | Observation |
| BCVA – best-corrected visual acuity; IOP – intraocular pressure; Hand motion – ability to perceive gross hand movement at close range; TID – three times daily; AC – anterior chamber; PPV – pars plana vitrectomy; GCIPL – ganglion cell–inner plexiform layer. IOP was not measured on Day 3 because the patient did not present for clinical examination. | ||||